Study guide
1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related)
Certified Genetic Counselor CGC
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics
2 Domain 1A: Clinical Information
1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review
3 Domain 1B: Human Development
1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development
4 Domain 1C: Chromosomal & Contiguous Gene Syndromes
1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)
5 Domain 1C: Hereditary Cancer Syndromes
1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition
6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions
1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework
7 Domain 2A: Pedigree & Risk Assessment
2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans
8 Domain 2B: Inheritance Principles
2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype
9 Domain 2B: Population Genetics & Variation
2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility
10 Domain 3A: Test Methodologies
3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics
11 Domain 3A: Variant Interpretation
3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework
12 Domain 3B: Testing Options
3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing
13 Domain 3C: Reproductive Risk Management
3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)
14 Domain 4A: Counseling Foundations
4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility
15 Domain 4A: Theories, Coping & Dynamics
4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics
16 Domain 4B: Communication & Education
4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making
17 Domain 5A–B: Finance & Client Resources
5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery
18 Domain 5C: Legal & Regulatory Requirements
5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing
19 Domain 5D: Professional Frameworks
5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education
20 Integration & Exam Strategy
6.1 Integrating Domains in Case-Based Practice & Exam Strategy
1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related)
Key Takeaways Explain This Topic AI
BRCA1 and BRCA2 are autosomal dominant high-penetrance genes; BRCA1 skews toward higher ovarian cancer risk and more triple-negative breast cancers, while BRCA2 more often associates with ER-positive breast cancer and male breast, prostate, and pancreatic risks
NCCN Genetic/Familial High-Risk Assessment guidelines frame testing criteria, age-triggered MRI/mammography, and risk-reducing salpingo-oophorectomy (RRSO) timing discussions for pathogenic variant carriers
PARP inhibitors exploit homologous recombination deficiency in BRCA-related cancers and are a key management concept genetic counselors should recognize when discussing treatment implications of a positive result
PALB2 is a high-risk breast cancer gene; ATM and CHEK2 are typically moderate-risk genes with gene-specific counseling that should not be collapsed into a BRCA-equivalent script
Risk-reducing mastectomy and RRSO counseling addresses residual risk, fertility/menopause, cascade testing, and psychosocial readiness—not only lifetime risk percentages
Last updated: August 2026
1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related)
Quick Answer: BRCA1 / BRCA2 pathogenic variants cause autosomal dominant hereditary breast and ovarian cancer (HBOC) with gene-specific tumor spectra. Counsel using NCCN Genetic/Familial High-Risk Assessment concepts for testing, MRI/mammography, and RRSO timing; distinguish high-risk genes ( BRCA1/2 , PALB2 ) from moderate-risk genes ( ATM , CHEK2 ). Positive results can open PARP-inhibitor treatment pathways in oncology.
Domain 1C cancer genetics items expect you to recognize features, natural history, surveillance, risk reduction, diagnostic strategy, and inheritance —not to memorize unpublished point estimates. Quote guideline families (commonly NCCN ) and well-established ranges; avoid inventing false precision.
Why HBOC Matters on the CGC Exam
Hereditary breast and ovarian cancer is the most frequently tested adult-onset cancer genetics vignette. Cases may start as a young breast cancer diagnosis, a ovarian/fallopian tube/primary peritoneal cancer, male breast cancer, pancreatic cancer with a suggestive pedigree, or cascade testing after a relative’s pathogenic variant. Your job is to map phenotype → gene differential → testing strategy → management implications for the consultand and relatives.
Inheritance and Biology
- Feature Teaching point
- Inheritance Autosomal dominant predisposition with incomplete penetrance and variable expressivity
- Gene class Tumor suppressors in homologous recombination (HR) DNA repair
- Knudson logic Germline “first hit”; somatic loss of the second allele in tumor tissue
Founder variants Notable in Ashkenazi Jewish populations ( BRCA1 185delAG, 5382insC; BRCA2 6174delT)—still confirm with full gene analysis when indicated
Pathogenic variants in BRCA1 or BRCA2 substantially elevate lifetime risks of female breast and ovarian cancers relative to population baselines. Exact percentages vary by study, ascertainment, and modifier factors; board-level teaching uses elevated, gene-specific ranges and points patients to current NCCN tables rather than a single memorized number.
BRCA1 vs BRCA2: Phenotype Differences
Dimension BRCA1 BRCA2
Female breast cancer High risk; enrichment for triple-negative (ER−/PR−/HER2−) tumors High risk; more often hormone receptor–positive histology
Ovarian / fallopian / peritoneal Generally higher ovarian cancer risk than BRCA2 Elevated ovarian risk, typically lower than BRCA1 on average
Male breast cancer Elevated vs population, but more characteristic of BRCA2 Classic association; male breast cancer is a testing red flag
- Prostate cancer Increased risk reported More consistently emphasized; earlier/aggressive disease possible
- Pancreatic cancer Increased Increased (often highlighted in counseling)
- Other Melanoma sometimes discussed Melanoma associations also discussed in literature
Exam trap: Do not treat BRCA1 and BRCA2 as interchangeable scripts. Histology, sex-specific cancers, and RRSO timing nuances differ. Both remain high-penetrance HBOC genes requiring structured surveillance and risk-reduction counseling.
Related Genes: PALB2, ATM, CHEK2 (High-Level)
Modern hereditary cancer panels expand beyond BRCA1/2 . Counselors must stratify by risk magnitude and organ-specific implications.
Gene Approximate risk tier (conceptual) Counseling anchors
PALB2 High-risk breast cancer gene; ovarian risk less dominant than BRCA1 Partner-and-localizer of BRCA2 in HR; breast MRI often considered; risk-reducing mastectomy may be discussed based on personal/family history and guidelines
ATM Moderate breast cancer risk Avoid collapsing into BRCA-equivalent RRSO defaults; heterozygous counseling differs from biallelic ataxia-telangiectasia
CHEK2 Moderate breast cancer risk (variant-dependent) Commonly includes discussion of breast surveillance intensification; ovarian risk generally not managed like BRCA1
Other HR-related genes Panel-dependent ( BARD1 , RAD51C/D , BRIP1 , etc.) Gene-specific ovarian vs breast emphasis—use current NCCN gene pages
Biallelic pathogenic variants in some of these genes cause rare recessive syndromes (e.g., Fanconi anemia pathway for certain BRCA2 / PALB2 genotypes; ataxia-telangiectasia for ATM ). When counseling a heterozygous adult, briefly note reproductive implications if both partners could be carriers.
Diagnostic / Testing Strategy
Phenotype- and pedigree-driven pretest counseling: cancer types, ages, pathology, ancestry, prior testing in the family.
Prefer testing an affected relative first when feasible; if unavailable, test the consultand with clear limitations.
Choose multi-gene panel vs targeted known-familial variant testing based on whether a familial pathogenic variant is already identified.
Interpret VUS cautiously—do not change surgical plans based on VUS alone.
Arrange cascade testing for relatives when a pathogenic/likely pathogenic variant is found.
Ashkenazi Jewish ancestry may prompt discussion of founder-variant strategies historically, but contemporary practice often still favors broader analysis when clinical criteria are met—follow current laboratory and guideline context.
Surveillance and Risk Reduction (NCCN-Style Concepts)
NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic guidelines (and related breast cancer screening guidelines) organize age to start annual breast MRI , mammography, clinical exams, and discussions of risk-reducing mastectomy and risk-reducing salpingo-oophorectomy (RRSO) .
Intervention Counseling themes
Breast MRI ± mammography Earlier start than average-risk screening for high-risk gene carriers; MRI sensitivity for dense breasts; false-positive anxiety
Risk-reducing mastectomy Greatest breast cancer risk reduction; does not eliminate residual risk entirely; reconstruction, body image, timing relative to childbearing
RRSO Major ovarian/fallopian cancer risk reduction for BRCA1/2 ; timing often gene- and age-informed (commonly discussed earlier for BRCA1 than BRCA2 in guideline tables); surgical menopause, bone/cardiovascular health, HRT nuances, fertility
Salpingectomy strategies Emerging/interval concepts may appear in counseling literature—distinguish established RRSO recommendations from evolving protocols
Pancreatic surveillance Considered in selected BRCA2 (and other) carriers with additional risk factors per specialty guidelines—not universal for every HBOC gene
Do not invent exact unpublished percentages on the exam essay of counseling; say “substantially elevated,” cite the guideline family, and individualize.
PARP Inhibitors and Oncology Management Concepts
Poly(ADP-ribose) polymerase (PARP) inhibitors exploit synthetic lethality in homologous recombination–deficient cells. For genetic counselors, the board-relevant points are:
A germline BRCA1/2 (and some other HR gene) finding can change treatment eligibility discussions with the oncology team.
Indications evolve (breast, ovarian, prostate, pancreatic contexts appear in oncology practice).
Counseling separates hereditary risk management for the patient and family from tumor-directed therapy , while explaining why germline results matter to both.
You are not prescribing; you are ensuring the patient understands why germline testing was ordered and how results may open targeted options alongside cascade prevention.
Putting It Together in a Counseling Session
Collect pathology (especially triple-negative breast cancer, high-grade serous ovarian) and pedigree.
Explain autosomal dominant inheritance and incomplete penetrance in plain language.
Contrast BRCA1 vs BRCA2 tumor spectra when relevant; introduce PALB2 /moderate-risk genes if panel testing is planned.
Preview management: intensified breast imaging, RRSO/mastectomy decisions, possible PARP-inhibitor relevance.
Plan disclosure, psychosocial support, and relative cascade testing.
HBOC fluency is the foundation for the next sections on Lynch/polyposis and rarer high-penetrance syndromes.